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Background: Frailty is a complex clinical syndrome associated with vulnerability to
adverse health outcomes. While frailty is thought to be common in chronic obstructive
pulmonary disease (COPD), the relationship between frailty and COPD-related outcomes
such as risk of acute exacerbations of COPD (AE-COPD) and hospitalizations is unclear.
Purpose: To examine the association between physical frailty and risk of acute exacerbations, hospitalizations, and mortality in patients with COPD.
Methods: A longitudinal analysis of data from a cohort of 280 participants was performed.
Baseline frailty measures included exhaustion, weakness, low activity, slowness, and undernutrition. Outcome measures included AE-COPD, hospitalizations, and mortality over 2
years. Negative binomial regression and Cox proportional hazard modeling were used.
Results: Sixty-two percent of the study population met criteria for pre-frail and 23% were
frail. In adjusted analyses, the frailty syndrome was not associated with COPD exacerbations. However, among the individual components of the frailty syndrome, weakness measured by handgrip strength was associated with increased risk of COPD exacerbations (IRR
1.46, 95% CI 1.09–1.97). The frailty phenotype was not associated with all-cause hospitalizations but was associated with increased risk of non-COPD-related hospitalizations.
Conclusion: This longitudinal cohort study shows that a high proportion of patients with
COPD are pre-frail or frail. The frailty phenotype was associated with an increased risk of
non-COPD hospitalizations but not with all-cause hospitalizations or COPD exacerbations.
Among the individual frailty components, low handgrip strength was associated with
increased risk of COPD exacerbations over a 2-year period. Measuring handgrip strength
may identify COPD patients who could beneﬁt from programs to reduce COPD
exacerbations.
Keywords: chronic obstructive pulmonary disease, frailty, weakness, handgrip strength
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Chronic obstructive pulmonary disease (COPD) is a signiﬁcant cause of morbidity and
remains the third leading cause of death in the United States.1 Acute exacerbations of
COPD (AE-COPD) frequently occur and place a signiﬁcant utilization and cost burden
on the US healthcare system.2,3 Additionally, AE-COPD have been shown to accelerate
declines in lung function, health-related quality of life, and increase hospitalizations
and mortality.4–7 Identifying patients at high risk may help target interventions to
reduce AE-COPD.8–10 Risk factors for AE-COPD include age, sex, forced expiratory
volume (FEV1), and frequent prior exacerbations.7–9,11,12
Frailty has been described as a state of decreased physiologic reserve causing
vulnerability to adverse events,13,14 and identiﬁes individuals who are at risk for
International Journal of Chronic Obstructive Pulmonary Disease 2020:15 1967–1976
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disability, adverse health outcomes, and increased allcause mortality.14–17 The frailty phenotype proposed by
Fried et al is widely accepted and is deﬁned as the presence of three or more of the following measures: exhaustion, weakness, slowness, low activity, and/or weight
loss,14,18 with pre-frailty deﬁned as having 1–2 frailty
measures.19
COPD patients are twice as likely to be frail than those
without COPD, and a review of 27 studies found that an
estimated 19% were frail, with 56% meeting criteria for
pre-frailty.19,20 The prevalence of frailty varies by setting,
ranging from 9% to 28% in the majority of studies,
whereas pre-frailty prevalence varies from 48% to
64%.19 Few longitudinal studies have examined the association of frailty with COPD outcomes such as
exacerbations,20 and have used heterogenous deﬁnitions
of frailty.19 Most studies have used questionnaires to
assess frailty, with few using objectively measured muscle
strength or gait speed to assess frailty in people with
COPD. A longitudinal study using the Fried criteria
found that mortality among frail COPD patients was four
times higher than non-frail patients.20 Longitudinal studies
using questionnaires to measure frailty have found an
increased risk of re-admissions and mortality in
COPD.13,21 Also, among participants in the National
Emphysema Treatment Trial, frail COPD participants had
an increased risk of all-cause hospitalization and worse
quality of life.22
Frailty is deﬁned as a syndrome; however, one of the
individual frailty components is muscle weakness measured by handgrip strength (HGS), which has been associated with increased risk of acute COPD exacerbations in
a cross-sectional study.23 Limb muscle dysfunction is
common in COPD and contributes to poor clinical outcomes including exercise tolerance and mortality.24,25
Importantly, limb muscle strength can be improved with
exercise training and is a modiﬁable risk factor for adverse
outcomes.
This study’s primary aim is to examine the relationship
between the frailty syndrome with the risk of COPD
exacerbations in a longitudinal outpatient cohort of
patients with COPD utilizing objectively measured muscle
strength and physical activity. We examined the impact of
grip strength and other individual components of frailty on
risk of adverse COPD outcomes. Additional aims are to
evaluate the associations between frailty and all-cause
hospitalizations,
non-COPD
hospitalizations,
and
mortality.
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Methods
Study Design
This study analyzed data collected as part of the COPD
Activity: Serotonin Transporter, Cytokine, and Depression
(CASCADE) study.26 Approvals were obtained by institutional review boards, in compliance with the Declaration
of Helsinki, at the three clinical sites: University of
Washington, VA Puget Sound Health Care System, and
University of Texas Health Science Center-San Antonio.
All participants provided written informed consent.
Inclusion criteria included a diagnosis of COPD, postbronchodilator FEV1/FVC <0.70% and FEV1% predicted
<80%, age ≥40 years, current or past cigarette use (>10
pack-years), and stable disease in the past 4 weeks.
Exclusion criteria were: non-COPD lung disease (eg,
asthma, diffuse parenchymal lung disease), chronic inﬂammatory diseases, lung cancer or metastatic cancer, severe
chronic kidney disease, uncompensated heart failure,
advanced liver disease, HIV/AIDS, chronic antibiotic or
oral prednisone use, bipolar disease, psychotic disorders,
or dementia.

Measures
Disease Severity
Measures of disease severity included: forced expiratory
volume in 1 second, body mass index (BMI), home oxygen use, Charlson co-morbidity index,27,28 COPD hospitalizations in the prior year, and dyspnea with Modiﬁed
Medical Research Council scale (mMRC).29 Individual
comorbidities were also examined including myocardial
infarction, angina, heart failure, peripheral vascular disease, stroke, hemiplegia, neurologic disease (multiple
sclerosis or Parkinson’s disease), pneumonia, ARDS,
drug abuse, peptic ulcer disease (history of endoscopy),
visual impairment, hearing impairment, degenerative disc
disease, diabetes, diabetes treatment (diet, oral hypoglycemics or insulin), diabetes complications (eye, kidney),
post-traumatic stress disorder, chronic kidney disease,
rheumatoid arthritis, osteoarthritis, osteoporosis, cirrhosis,
leukemia, lymphoma, and non-metastatic cancer.

Frailty
Using baseline data, we adapted the 5 components of the
frailty phenotype model deﬁned by Fried using the following established measures:14 1) Exhaustion was deﬁned as
a score of ≤55 on the vitality scale of the SF-36 quality of
life measure, an approach used in other studies of
frailty;30,31 2) Weakness was assessed using a Jamar
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dynamometer (Fabrication Enterprises, White Plains,
NY).32 While standing, participants were instructed to
squeeze the grip handle as hard as they were able using
their dominant hand with a 90-degree ﬂexion at the elbow.
The measurement was repeated 3 times and the best results
used. Low HGS was deﬁned using cutoffs by Fried which
is commonly used and based on one cohort of older
participants.14 Because our cohort included younger participants than in the Fried study, we also performed
a sensitivity analysis using a statistically based cutoff of
2 standard deviations below the gender-speciﬁc peak mean
from 12 large population studies by Dodd et al which
included participants <65 years;33 3) Participants wore
a StepWatch 3 Activity Monitor (OrthoCare Innovations,
Washington, DC)34,35 during waking hours for 7 consecutive days. Low activity was deﬁned as total daily step
count <2500,36 4) Slowness was deﬁned as a cadence
<30 steps/minute,37 obtained using the StepWatch 3
Activity Monitor reﬂecting the average steps/minute during the top 30 one-minute periods each day; and, 5)
Chronic undernutrition deﬁned using the BMI cutoff of
≤21 as described in the BODE index.29

pairwise comparison of baseline characteristic by frailty status with adjustment for multiple testing with Bonferroni
correction. Next, we modeled the risk of moderate-tosevere exacerbations, hospitalizations, and mortality over 2
years for each frailty measure. Regression models were
adjusted for the following baseline covariates: age, sex,
Charlson comorbidity index ≥1, supplemental home oxygen
use, COPD hospitalizations in the prior year, FEV1% predicted, and mMRC score. The logarithm of the total number
of days of follow-up was included in the model with the
coefﬁcient constrained to 1 to measure time at risk. Due to
over-dispersion of AE-COPD and hospitalization data, negative binominal modeling was used producing incidence rates
ratios. Cox proportional hazards modeling was used for
survival analysis. To examine whether individual comorbidities might confound the relationship between frailty and
COPD exacerbations, we examined the association between
comorbid conditions and both frailty and COPD exacerbations. A sensitivity analysis was performed with variables
associated with frailty and COPD exacerbations at p <0.10
level to assess whether the coefﬁcient for frailty changed by
>10%. Analyses were conducted using Stata 15.0 (StataCorp
LP, College Station, TX).

Other Covariates
Baseline demographic characteristics and smoking status
were obtained by questionnaire. Peak performance,
a measure of physical activity, was measured using the
StepWatch Activity Monitor and deﬁned as the highest
number of steps per minute during the top 30 one-minute
periods each day.

Outcomes
Moderate-to-severe acute COPD exacerbations during the
2-year follow-up were deﬁned as exacerbations treated with
prednisone and/or antibiotics, treated in the emergency
department or requiring hospitalization. AE-COPDs were
identiﬁed through standardized phone surveys every 3 to 4
months. All-cause mortality was reported to research coordinators throughout the study duration.

Statistical Analysis
We compared unadjusted participant characteristics by the
frailty phenotype deﬁned by Fried’s study: Non-frail (0
frailty measures), Pre-frail (1–2 frailty measures), and Frail
(≥3 frailty measures) using Wald test with robust standard
errors of linear regression models for continuous variables,
and Wald chi-square test for categorical variables. For signiﬁcant comparisons, we calculated p-values for each
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Results
Participant Characteristics and Frailty
Measures
This analysis included 280 participants with complete
measures of HGS, physical activity data, and longitudinal
follow-up out of 302 enrolled in the CASCADE study.
Overall, there was a high prevalence of frailty measures
(Figure 1).
Exhaustion (SF 36-vitality scale score < 55) was
present in 65.6% of participants, slowness (cadence <
30 steps/min) in 52.8%, weakness (low HGS) in 30.1%.
Nearly two-thirds of participants fell into the pre-frail
category with 1–2 frailty measures (62.4%).
Approximately a quarter had 3 or more frailty measures
(23.4%) consistent with the frailty phenotype. When
using the criteria by Dodd et al to deﬁne weakness
(low handgrip strength), there was a slightly larger proportion of patients classiﬁed as having weakness (37.2%
vs 30.1%). The proportion of patients who were pre-frail
and frail were similar using the Dodd HGS criteria (nonfrail 13.1%, pre-frail 62.1%, frail 24.8%). The study
cohort was mainly white non-Hispanic (88%), male
(80%) with mean age of 68 years. Non-white participants
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exhaustion was associated with higher risk of moderateto-severe AE-COPD (IRR 1.47, 95% CI 1.07–2.01) in
unadjusted models but not after adjustment for covariates (IRR 1.25, 95% CI 0.93–1.69). Only weakness,
measured by low HGS deﬁned using Fried criteria, was
associated with increased risk of AE-COPD (IRR 1.46,
95% CI 1.09–1.97) in adjusted models. Sensitivity analysis
using low HGS as deﬁned by Dodd also showed an association with increased risk of AE-COPD (IRR 1.40, 95%
CI 1.05–1.85). The frailty measures of slowness and
undernutrition were not associated with increased risk of
AE-COPD in unadjusted or adjusted models. Low physical
activity was associated with a decreased risk of AE-COPD
in adjusted models.
In sensitivity analyses, we examined whether individual comorbidities were associated with frailty and COPD
exacerbations, and found that only neurologic disease
(multiple sclerosis and Parkinson’s disease) were associated with both frailty and COPD exacerbations at
a p<0.10. Adding neurologic disease to the ﬁnal model
did not change the results (data not shown).

Frailty and Hospitalizations

Figure 1 Prevalence of frailty measures at baseline. (A) Prevalence of individual
frailty measures: Exhaustion (Short Form Health Survey 36 scale score <50);
Weakness (low handgrip strength); Slowness (Cadence <30 steps per minute);
Low activity (total daily steps <2500); Undernutrition (body mass index ≤21). (B)
Prevalence of frailty phenotypes: non-frail (0 frailty measures); pre-frail (1–2 frailty
measures); Frail (≥3 frailty measures).

were more likely to be pre-frail or frail (p = 0.04).
Comparison of the baseline characteristics found that
frail participants were more likely to use home supplemental oxygen (p < 0.001; Table 1).

Frailty and Acute Exacerbations of COPD
The unadjusted rates of moderate-to-severe exacerbations
did not differ signiﬁcantly by frailty phenotype class
(Table 2).
Results from adjusted negative binomial regression
models examining the association between frailty and
acute exacerbations are summarized in Table 3.
There was no association between the frailty phenotype
(≥3 criteria) and increased risk of moderate-to-severe AECOPD. Among the individual frailty components,
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Those deﬁned as frail (≥3 frailty measures) had an
increased risk of all-cause hospitalization in the unadjusted
analysis using the frailty measure of weakness as deﬁned
by Fried et al (IRR 2.26, 95% CI 1.09–4.71), but failed to
have a signiﬁcant association in adjusted analyses (IRR
1.96, 95% CI 0.92–4.19). In both unadjusted and adjusted
analyses, individual frailty measures of exhaustion, weakness, slowness, low activity, and undernutrition were not
signiﬁcantly associated with risk of all-cause hospitalizations (Table 3).
In an analysis restricted to non-COPD-related hospitalizations, participants with the frailty phenotype were at
increased risk of non-COPD-related hospitalizations (IRR
2.62, 95% CI 1.00–6.84, p = 0.05). Among the individual
frailty measures, slowness was signiﬁcantly associated with
increased risk of non-COPD hospitalizations whereas there
was a non-signiﬁcant increased risk of non-COPD hospitalizations with exhaustion, weakness and low activity.
In a sensitivity analysis using the Dodd et al criteria for
weakness based on low handgrip strength, similar results
were seen (Table 4).

Frailty and Mortality
There was a low number of deaths in our study population
with most deaths occurring in those who were frail (Table
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Table 1 Participant Characteristics (N=280)
Not Frail n=40

Pre-Frail n=176

Frail n=64

P-value*

Age, yr, mean (SD)

69.4 (8.0)

66.9 (8.4)

68.6 (9.2)

0.14

Sex, female (%)

10 (25.0)

34 (19.3)

12 (18.2)

0.67

Race, non-White (%)

0

23 (13.1)

10 (15.2)

0.04b

Mean (SD)

28.5 (3.9)

28.0 (5.9)

28.0 (7.9)

0.82

Low BMI (≤21)

0

12 (6.8)

17 (25.8)

<0.001a,b,c

8 (20.0)

47 (26.7)

21 (31.8)

0.41

49.5 (15.1)

46.9 (15.4)

36.9 (14.5)

<0.001b,c

BMI

Current smoker (%)
COPD Disease severity
FEV1% predicted mean (SD)

0.002b,c

GOLD severity category
Moderate (50–80%)

20 (50.0)

78 (44.3)

Severe (30–49%)

14 (35.0)

71 (40.3)

30 (45.5)

Very severe (<30%)
mMRC, mean (SD)

6 (15.0)
1.3 (0.8)

27 (15.3)
1.9 (1.1)

22 (33.3)
2.6 (1.0)

<0.001a,b,c

Home supplemental oxygen (%)

9 (22.5)

51 (29.0)

36 (54.6)

<0.001b,c

≥ 1 COPD hospitalization prior yr (%)

14 (35)

75 (43)

35 (52)

0.23

Charlson Comorbidity Index, ≥1 (%)
Non-metastatic cancer**

18 (45.0)
7 (17.5)

85 (48.3)
19 (10.8)

35 (53.0)
9 (13.6)

0.70
0.48

Neurologic disease#

3(7.5)

3 (1.7)

1 (1.5)

0.09

1301 (277)

1136 (343)

844(377)

<0.001a,b,c

Total Daily Steps, mean (SD)
Low physical activity (<2500 steps/day)

7943 (2978)
0

6675 (3139)
3 (1.7)

3030 (1981)
36 (54.6)

<0.001b,c
<0.001a,b,c

Slowness (cadence <30 steps/minute)

0

85 (48.3)

64 (97.0)

<0.001a,b,c

36.1 (5.0)

31.6 (7.5)

20.8 (6.8)

<0.001a,b,c

60.9 (5.4)
0

46.2 (11.7)
124 (70.5)

39.2 (9.9)
62 (93.9)

<0.001a,b,c
<0.001a,b,c

Comorbidity

Physical Function
6MWT, mean (SD), feet
Physical Activity Data

##

Peak Performance, mean (SD)
SF-36 Vitality Score
Mean Vitality Score (SD)
Low Vitality Score (≤55)
Handgrip strength, Kg
Mean Handgrip strength (SD)

35.2 (8.3)

33.9 (9.6)

26.2 (7.8)

<0.001b,c

Low handgrip strength by Fried criteria

0

38 (21.6)

48 (72.7)

<0.001a,b,c

Low handgrip strength by Dodd criteria

3 (7.5)

52 (29.6)

50 (75.8)

<0.001a,b,c

Notes: *P-value for Wald test with robust standard errors of linear regression models for continuous variables, and Wald chi-square test for categorical variables. **Nonskin cancer, no lymphoma or leukemia. #Multiple sclerosis or Parkinson’s. ##Peak performance is deﬁned as the top steps/minute during the top 30 one-minute periods
each day. ap<0.0167 comparing not frail and pre-frail participants. bp<0.0167 comparing not frail and frail participants. cp<0.0167 comparing pre-frail and frail participants.
Abbreviations: SD, standard deviation; BMI, body mass index; mMRC, Modiﬁed Medical Research Council Dyspnea Scale; SF-36, Short Form Health Survey 36.

2). In unadjusted analysis, there was an association
between weakness as deﬁned by Dodd and increased risk
of mortality (HR 2.36, 95% CI 1.03–5.38). In all other
unadjusted and adjusted analysis, there was no signiﬁcant
association between frailty measures and death (Table 5).
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Discussion
In this prospective cohort study of COPD patients, the prevalence of pre-frailty and frailty was high. The frailty phenotype was associated with an increased risk of non-COPD
hospitalizations, but not with the risk of moderate-to-severe
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Table 2 Mean Annual Exacerbation, Hospitalization Rates and Mortality by Frailty Category
Outcome

Not Frail n=40

Pre-Frail n=176

Frail n=64

P-value*

Moderate-to-severe exacerbations per year, mean (SD)
All-cause hospitalizations per year, mean (SD)

0.59 (0.70)
0.20 (0.41)

0.75 (0.89)
0.34 (0.65)

0.87 (1.16)
0.49 (0.68)

0.27
0.02b

Non-COPD hospitalizations per year, mean (SD)

0.10 (0.23)

0.17 (0.41)

0.22 (0.37)

0.12

Mortality, n (%)

3 (7.5)

8 (4.6)

10 (15.2)

0.02c

Notes: *P-value for Wald test with robust standard errors of linear regression models for continuous outcome variables and Wald chi-square test for mortality frequency.
b
p<0.0167 comparing not frail and frail participants. cp<0.0167 comparing pre-frail and frail participants.

Table 3 Associations Between Frailty Measures and Acute COPD Exacerbations and All-Cause Hospitalizations Using Handgrip
Strength Based on Fried et al Criteria
Frailty Measures*

Moderate-Severe COPD

All-Cause

Non-COPD

Exacerbations

Hospitalizations

Hospitalizations

Adj. IRR (CI)**

p-value

Adj. IRR (CI)**

p-value

Adj. IRR (CI)**

p-value

Number of frailty measures
Non-frail (0)

ref

Pre-frail (1–2)
Frail (≥3)

1.13 (0.74–1.72)
1.14 (0.69–1.89)

0.57
0.62

1.36 (0.70–2.64)
1.96 (0.92–4.19)

ref
0.36
0.08

1.58 (0.68–3.70)
2.62 (1.00–6.84)

ref
0.29
0.05

Individual frailty components
Exhaustion (SF 36-vitality score <55)

1.25 (0.93–1.69)

0.14

1.49 (0.95–2.33)

0.09

1.51 (0.86–2.66)

0.15

Weakness (Low HGS based per Fried)

1.46 (1.09–1.97)

0.01

1.27 (0.81–2.01)

0.30

1.23 (0.70–2.18)

0.47

Slowness (Cadence <30 steps/min)
Low activity (Total daily steps <2500)

0.86 (0.64–1.16)
0.55 (0.35–0.88)

0.32
0.01

1.14 (0.74–1.76)
1.03 (0.56–1.91)

0.55
0.93

1.96 (1.13–3.38)
1.33 (0.61–2.90)

0.02
0.48

Undernutrition (BMI ≤21)

0.95 (0.61–1.47)

0.80

0.93 (0.47–1.85)

0.84

0.83 (0.34–2.04)

0.69

Notes: *Each frailty measure represents an independent model. **Adjusted for Age, Sex, Charlson comorbidity index ≥ 1, FEV1, nMRC, Home O2, Prior COPD
hospitalizations in the past year.
Abbreviations: IRR, incidence rate ratio; CI, conﬁdence interval; SF-36, Short Form Health Survey 36; HGS, handgrip strength; BMI, body mass index.

Table 4 Sensitivity Analysis: Associations Between Frailty Measures and Acute COPD Exacerbations and All-Cause Hospitalizations
Using Handgrip Strength Based on Dodd et al Criteria
Frailty Measures*

Mod-Severe COPD

All-Cause

Non-COPD

Exacerbations

Hospitalizations

Hospitalizations

Adj. IRR (CI)**

p-value

Adj. IRR (CI)**

p-value

Adj. IRR (CI)**

p-value

Number of frailty measures
Non-frail (0)

Ref

Pre-frail (1–2)
Frail (≥3)

1.13 (0.73–1.75)
1.12 (0.67–1.87)

0.59
0.65

1.16 (0.59–2.27)
1.83 (0.86–3.88)

0.67
0.12

1.30 (0.55–3.08)
2.62 (1.02–6.74)

0.54
0.05

1.40 (1.05–1.85)

0.02

1.27 (0.83–1.96)

0.27

1.47 (0.87–2.49)

0.15

Weakness (Low HGS based

Ref

Ref

per Fried)
Notes: *Each frailty measure represents an independent model. **Adjusted for Age, Sex, Charlson comorbidity index ≥ 1, FEV1, mMRC, Home O2, Prior COPD
hospitalizations in the past year.
Abbreviations: IRR, incidence rate ratio, CI, conﬁdence interval HGS, handgrip strength.

exacerbations in adjusted analyses. Of the ﬁve standard measures of frailty, only handgrip strength was independently
associated with increased risk of moderate-to-severe AECOPD.
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Our ﬁndings add to the existing evidence that prefrailty and frailty are common among persons with
COPD. The prevalence of the frailty phenotype using the
criteria of Fried et al in this outpatient cohort of COPD
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Table 5 Associations Between Frailty Measures and Mortality
Frailty Measures*

Adjusted HR (CI)**

Number of frailty measures
0

Ref

1–2

0.58 (0.15–2.29)

0.43

≥3

1.47 (0.34–6.38)

0.61

Individual frailty components
Exhaustion (SF 36-vitality scale score <55)

0.83 (0.34–1.99)

0.67

Weakness (Low HGS per Fried)

1.31 (0.33–1.96)

0.30

Weakness (Low HGS per Dodd)
Slowness (Cadence <30 steps/min)

1.49 (0.61–3.61)
1.93 (0.67–5.53)

0.38
0.22

Low activity (Total daily steps <2500)

1.16 (0.36–3.76)

0.81

Undernutrition (Low weight BMI ≤21)

1.87 (0.58–6.01)

0.29

Notes: *Each frailty measure represents an independent model. **Adjusted for Age, Sex, Charlson comorbidity index ≥ 1, FEV1, MMRC, Home O2, Prior
COPD hospitalizations in the past year.
Abbreviations: HR, hazard ratio; SF-36, Short Form Health Survey 36; HGS, handgrip strength; BMI, body mass index.

patients was similar to the pooled prevalence described in
a systematic review by Marengoni (23% vs 19%,
respectively).19 Similarly, the prevalence of pre-frailty in
this study was 64%, compared to 56% described by
Marengoni et al.19
Like other studies we found that frailty is associated
with non-COPD hospitalizations, however, the frailty syndrome as a whole was not associated with the key COPD
outcome of exacerbations. When the individual components of the frailty syndrome were examined separately,
however, handgrip strength was predictive of COPD
exacerbations. To the best of our knowledge, this is the
ﬁrst study that describes an association between low HGS
and increased risk of AE-COPD in a prospective analysis,
and the results are consistent with a cross-sectional study
that found that HGS was associated with risk of COPD
exacerbations in the past year.23,38 HGS is also associated
with quality of life measured with the EuroQOL EQ-5D in
COPD,39 and another measure of limb muscle strength,
quadriceps strength, predicted mortality in COPD.25 Limb
muscle dysfunction is common in COPD, and is related to
poor exercise tolerance.24 The exact mechanism in which
low HGS contributes to increased risk of AE-COPD has
not been well understood, however. The relationship
between HGS and exacerbations was similar whether we
used the same cut-offs for low HGS from Fried’s original
study, or using the reference range by Dodd et al that
deﬁned low HGS as 2 standard deviations below the predicted peak handgrip strength as an adult.14,33
Frailty is a broader syndrome than low handgrip
strength and is characterized by a physiologic state of
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decreased reserve causing vulnerability to adverse
events.40,42 Overall the relationship between frailty and
COPD outcomes is unclear.19,42 We used Fried’s framework to deﬁne frailty based on the presence of ≥3 out of 5
frailty measures.14 Since we did not have identical measures used to deﬁne the Fried criteria, we used externally
validated criteria. We deﬁned frailty measures of slowness
and low activity with objectively measured data obtained
through a validated accelerometer, undernutrition by baseline BMI, and exhaustion by the SF 36-vitality scale score.
Interestingly, we found that except for handgrip
strength, the other 4 measures of physical frailty were
not associated with a signiﬁcantly increased risk of AECOPD. Exhaustion showed a trend towards increased risk
of exacerbations, but slowness, low activity and undernutrition were not associated with exacerbations. Low
physical activity, deﬁned as total daily steps <2500,36
was associated with a decreased exacerbation risk (IRR
0.55, 95% CI 0.35–0.88), but there was no association
between low physical activity and risk of non-COPD hospitalizations. This result was unexpected as prior studies
have shown that decreasing step count is associated with
an increased risk of acute exacerbations and COPD
hospitalizations.43–45 The reason why low physical activity
might reduce exacerbation risk is unclear, although
patients with low step counts may theoretically be
limiting potential environmental exposures triggering
exacerbations.
We had few participants with undernutrition (10%) and
were not able to assess weight loss prior to baseline visit,
limiting the utility of this frailty measure. Therefore, in
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COPD, physical measures of frailty such as slowness, low
activity, and undernutrition appear to be less predictive of
AE-COPD than weakness or exhaustion. The participants
in this study had moderate-to-severe COPD and therefore
it is possible that some of the frailty components such as
slowness and low activity are already captured in the
COPD severity measures of FEV1, dyspnea (mMRC)
and home oxygen use. We found that frailty was associated with increased risk of non-COPD-related hospitalizations. This suggests that the frailty phenotype is still an
important
risk
factor
for
non-COPD-related
hospitalizations.
Although the frailty phenotype was associated with
increased risk of mortality, this were not statistically signiﬁcant. We suspect this was largely driven by a lack of
statistical power given the low number of deaths (21
deaths) over the two-year course of the study. This is
supported by the fact that two factors that commonly
associated with mortality in COPD (low BMI29 and
weakness46) had increased point estimates for morality
but were not statistically signiﬁcant.
Our ﬁnding that HGS is the main frailty measure predictive of AE-COPD supports other studies that have suggested that HGS alone may be a useful marker of frailty and
those with decreased physiologic reserve.47,48 Assessing
weakness by measuring handgrip strength can be easily
done in clinical practice for COPD patients and could provide important prognostic information and identify patients
who may beneﬁt from targeted interventions.18,19 Prior studies have shown reversibility in frailty and sarcopenia status
with pulmonary rehabilitation.19,40,41,49 More detailed longitudinal studies on frailty, weakness, and COPD-related outcomes are warranted in addition to further study on the
potential impact of pulmonary rehabilitation on COPD outcomes in frail patients.
Several limitations are worth noting. The majority of our
sample were men and frailty is more common in older
women.50 Additionally, due to the primary aim of the main
study, participants were excluded if they were chronically
using oral corticosteroids or had chronic inﬂammatory states
other than COPD. Although these exclusion criteria reduced
the confounding because of steroids or other inﬂammatory
states on the relationship between frailty and COPD outcomes,
they may limit the generalizability of our ﬁndings and may
have selected for a heathier baseline study population. Another
potential limitation is the use of frailty measure deﬁnitions that
did not exactly match the original Fried deﬁnitions. However,
similar to others,22 we were careful to use externally
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developed criteria to represent the measures of exhaustion,
slowness, low physical activity, and undernutrition/weight
loss.
The use of accelerometer data from a 7-day period to
deﬁne slowness and low physical activity may be biased by
the Hawthorne effect, in which participants behave differently initially due to being observed but over time return to
their usual physical activity not captured by the accelerometer. In the ﬁnal model to predict non-COPD hospitalizations, we were not able to adjust for prior non-COPD
hospitalizations which may have inﬂuenced the results. As
previously discussed, the low number of deaths over the
study duration likely resulted in an underpowered analysis
for evaluation between frailty and mortality. Finally, exacerbation and hospitalization data were obtained through regular surveys, but ultimately reliant on patient self-report.

Conclusion
The results of this longitudinal cohort study show a high
proportion of patients with COPD are either frail or prefrailty of frailty, and that the individual frailty measure of
weakness, as deﬁned by low handgrip strength, was signiﬁcantly associated with increased risk of moderate-to-severe
acute exacerbations of COPD. The frailty phenotype was not
associated with COPD exacerbations but was associated with
an increased risk of non-COPD-related hospitalizations.
Evaluating weakness as measured by low handgrip strength
in patients with COPD identiﬁes a high-risk population that
could potentially beneﬁt from targeted interventions to prevent exacerbations and for interventions that can improve
muscle weakness in COPD such as pulmonary rehabilitation.
Future studies should examine whether interventions for
frailty and weakness may reduce adverse outcomes in COPD.

Abbreviations
AE-COPD, acute exacerbations of chronic obstructive pulmonary disease; BMI, body mass index; CASCADE Study,
COPD Activity: Serotonin Transporter, Cytokine, and
Depression Study; CI, conﬁdence interval; COPD, chronic
obstructive pulmonary disease; FEV1, forced expiratory
volume; FVC, forced vital capacity; HGS, handgrip strength;
IRR, incident rate ratio; SD, standard deviation.
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